Frisium (Clobazam) 10mg 10 x 10 Tablets / Strip

Frisium (Clobazam)

Clobazam, marketed under the brand names Frisium and Urbanol, is a benzodiazepine derivative. It binds to specific GABA receptors in the central nervous system (CNS), including the limbic system and reticular formation. This results in increased permeability of neuronal membranes to chloride ions, leading to the inhibitory effect of GABA, which causes hyperpolarization and stabilization.

Clobazam is well absorbed from the gastrointestinal tract when taken orally, with peak plasma concentrations achieved after 1-4 hours. It rapidly crosses the blood-brain barrier and has a protein-binding capacity of 85%. The drug undergoes hepatic metabolism through demethylation and hydroxylation. It is primarily excreted through the urine, both as unchanged drug and metabolites, with an elimination half-life of 18-42 hours.

The indications for clobazam are not available in the provided information.

Clobazam may cause adverse reactions such as constipation, anorexia, nausea, dizziness, fine tremors, worsening of respiratory symptoms in predisposed individuals, ataxia, drowsiness, headache, confusion, loss of libido, motor dysfunction, dependence, visual disturbances, and weight gain. Respiratory depression can be a potentially fatal side effect.

Treatment includes emptying the stomach through induced vomiting or gastric lavage within one hour of ingestion. Forced diuresis or hemodialysis are unlikely to be effective.

There are potential drug interactions to be aware of. When administered with phenytoin, phenobarbital, or carbamazepine, clobazam’s hepatic clearance may increase. Cimetidine may increase clobazam levels. Concurrent use of alcohol, hypnotics, and sedative antidepressants can potentiate the CNS side effects of clobazam.

The recommended dosage of clobazam for oral administration varies depending on the indication. The recommended pediatric dose for children aged 3-12 years starts at 125 mcg/kg twice daily, with gradual increases every 5 days. The usual maintenance dose is 250 mcg/kg twice daily, with a maximum dose of 500 mcg/kg twice daily. Elderly or debilitated patients may require a lower dose of 10-20 mg daily. Dose adjustments may be necessary in patients with renal or hepatic impairment.

The provided information does not mention any interference with laboratory tests.